|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Propofol repressed hepatocellular carcinoma Huh-7 and HepG2 cell growth and metastasis at least by elevating DGCR5 and hereafter inactivating Raf1/ERK1/2 and Wnt/β-catenin pathways.
|
31538334 |
2020 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
The elevated level of Activin A enhanced the invasive ALDH<sup>hi</sup> CSC-like phenotypes and PCa proliferation by activation of Smad and ERK1/2 signaling driving metastasis.
|
31740783 |
2020 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Here we report a Tamoxifen-controllable Twist1a-ERT2 transgenic zebrafish line as a new animal model for metastasis research, and demonstrate that this model can serve as a novel platform for discovery of anti-metastasis drugs targeting metastatic dissemination of cancer cells.
|
31748280 |
2020 |
|
Malignant neoplasm of stomach
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
<i>HOXA13</i> overexpression promotes proliferation and metastasis partly via activation of Erk1/2 in GC.
|
30881033 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
K-ras-ERK1/2 down-regulates H2A.X<sup>Y142ph</sup> through WSTF to promote the progress of gastric cancer.
|
31151422 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
These data indicate that inhibition of ERK1/2 in cancer-associated pancreatic stellate cells suppresses cancer-stromal interaction and metastasis.
|
31133044 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Biofunctional investigations revealed a tumor-suppressor role of WNK2: its inactivation led to ERK1/2 signaling activation in HCC cells, tumor-associated macrophage infiltration, and tumor growth and metastasis.
|
31349001 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Compared with the inhibition of ITGA6 or RPSA alone, the downregulation of both ITGA6 and RPSA weakened invasion and metastasis to a greater extent and led to the simultaneous downregulation of p-AKT and p-ERK1/2.
|
30894280 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Knockdown of SP1/Syncytin1 axis inhibits the proliferation and metastasis through the AKT and ERK1/2 signaling pathways in non-small cell lung cancer.
|
31397118 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
As a key regulator of angiogenesis, it promotes tumor survival, growth, and metastasis through the activation of the downstream protein kinase B (AKT) and extracellular signal-regulated kinase (ERK 1/2) activation.
|
30682194 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
<i>HOXA13</i> overexpression promotes proliferation and metastasis partly via activation of Erk1/2 in GC.
|
30881033 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
GLI1 activation by non-classical pathway integrin α<sub>v</sub>β<sub>3</sub>/ERK1/2 maintains stem cell-like phenotype of multicellular aggregates in gastric cancer peritoneal metastasis.
|
31366904 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Our findings revealed that the newly identified ATP-P2RX6-Ca<sup>2+</sup>-p-ERK1/2-MMP9 signaling facilitates RCC cell invasion and metastasis.
|
31159832 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Ribosomal S6 Kinase 2 (RSK2) is a downstream target of ERK1/2 in MAPK/ERK pathway and inhibition of RSK2 suppresses the tumorigenesis and metastasis of neoplasm.
|
31207212 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Functionally, knockdown of HK2 in ovarian cancer cell lines and ascites-derived tumor cells hindered lactate production, cell migration and invasion, and cell stemness properties, along with reduced FAK/ERK1/2 activation and metastasis- and stemness-related genes.
|
31212816 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We also identified that the suppressive effect of miR-449a on metastasis could be mediated by downregulating SRC and that miR-449a could suppress AKT and ERK1/2 pathway activation in endometrial cancer cells.
|
30719151 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
PosttranslationalModification
|
phenotype |
BEFREE |
MiR-22 downregulated the expression of NK1R-Tr and ERα to delay and weaken phosphorylation of ERK1/2 to inhibit proliferation and metastasis of breast cancer cells.
|
30502362 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Here, we also observed the reduction of the VEGF, Akt, pAkt, ERK1/2 and pERK1/2 proteins levels and the inhibition of proliferation and metastasis in CBS knockdown HepG2 cells.
|
30534696 |
2019 |
|
Malignant neoplasm of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
<b>Objective:</b> We explored the effects of H3<sup>K18ac</sup> on Ras-ERK1/2-affected lung cancer cell phenotypes.
|
31613681 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our study suggests that miR-93 promoted PC progression and metastasis by repressing DAB2 to activate Akt/ERK1/2 pathway, and elevation of DAB2 and inactivation of Akt/ERK1/2 might be a potential therapeutic target for PC by GTP.
|
30543885 |
2019 |
|
Malignant neoplasm of prostate
|
0.400 |
Biomarker
|
disease |
BEFREE |
Further top five genes viz Rhoa, PI3KCA, CDC42, MAPK3, TP53 were used for Enrichment analysis which revealed their association with vital cellular and functional pathways in prostate cancer indicating their potential as candidate biomarkers in prostate cancer.
|
30937635 |
2019 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
The mechanism elucidation concerning the ERK1/2 and p38 kinases and transcription factor c-jun/AP-1 might contribute another idea to the development of chemotherapy strategy for the gastric cancers in the future.
|
30011079 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
In conclusion, CAF‑derived HGF promotes angiogenesis, VM and mosaic vessel formation via PI3K/AKT and ERK1/2 signaling in gastric cancer and HGF may serve as a potential therapeutic target for cancer anti‑vascular treatment.
|
29917165 |
2018 |
|
Malignant neoplasm of stomach
|
0.400 |
Biomarker
|
disease |
BEFREE |
Inhibition of DAB2IP enhances gastric cancer cell growth and metastasis through targeting the ERK1/2 signaling, indicating that it may serve as a potential target for treatment of gastric cancer.
|
29743885 |
2018 |
|
Neoplasm Metastasis
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
Expression of ERK1/2 was downregulated, PLCγ was only expressed at the invasive front and in metastasis.
|
29976164 |
2018 |